Suppr超能文献

AAIR起搏在特定病态窦房结综合征患者中的安全性和有效性。

Safety and efficacy of AAIR pacing in selected patients with sick sinus syndrome.

作者信息

Senaratne Janek, Herath Thiloththama Thisaranie, Beaudette Diane, Irwin Marleen, Gulamhusein Sajad, Senaratne Manohara Piyasiri

机构信息

Division of Cardiology, University of Alberta.

Division of Cardiology, Grey Nuns Community Hospital, Edmonton, Alberta, Canada.

出版信息

Medicine (Baltimore). 2018 Oct;97(42):e12833. doi: 10.1097/MD.0000000000012833.

Abstract

BACKGROUND

The DANPACE study suggested implanting dual-pacing dual-sensing dual-response rate-adaptive (DDDR) pacemakers in patients with sick sinus syndrome, even though 90.7% of their atrial-pacing atrial-sensing inhibited-response rate-adaptive (AAIR) group did not require upgrade. Most centers implant DDDR pacemakers due to risk of future atrioventricular (AV) block. Given that AAIR pacemakers are less expensive, have one less lead with potentially one less point of complication, we question whether DDDR pacemakers are superior to AAIR pacemakers. We aim to describe long-term outcomes of AAIR implants.

METHODS

Patients presenting to the Grey Nuns Hospital in Edmonton, Canada from 1990 to 2012 with sick sinus syndrome without AV block had AAIR pacemakers implanted. Outcomes that were measured over the follow-up time included need for ventricular lead reoperation, incidence of AV block and incidence of sudden cardiac death from AV block.

RESULTS

During this period, 330 patients presented with sick sinus syndrome. Eighty-seven (26.4%) patients met criteria for and received AAIR pacemakers. Seventy-eight (91.8%) did not require upgrade over mean follow-up of 10.6 ± 0.6 years. Amongst this group, 31 patients (39.7%) were alive, whereas 47 (60.3%) were deceased at end of follow-up due to other comorbidities. No sudden deaths were attributable to AV block. Only 7 patients (8.2%) required ventricular lead reoperation: 2 (2.4%) presented urgently with symptomatic AV block; 3 (3.5%) had atrial fibrillation requiring beta-blockade; 1 (1.2%) had atrial lead dislodgment; and 1 (1.2%) was electively upgraded at battery end-of-life.

CONCLUSIONS

This study looks at safety of AAIR pacemakers with only 2.4% of patients developing AV block requiring urgent upgrade. Approximately 91.8% of patients remained with their original AAIR pacemakers (mean follow-up 10.6 vs 5.4 years in DANPACE). Our findings are similar to the DANPACE study but our conclusions are different as we believe AAIR pacing should be considered for selected patients with sick sinus syndrome without AV block.

摘要

背景

DANPACE研究表明,对于病态窦房结综合征患者,应植入双腔起搏、双感知、双反应频率自适应(DDDR)起搏器,尽管其心房起搏、心房感知、抑制反应频率自适应(AAIR)组中90.7%的患者不需要升级。由于未来发生房室(AV)传导阻滞的风险,大多数中心植入DDDR起搏器。鉴于AAIR起搏器成本较低,少一根导线且潜在并发症点也少一个,我们质疑DDDR起搏器是否优于AAIR起搏器。我们旨在描述AAIR起搏器植入的长期结果。

方法

1990年至2012年期间,加拿大埃德蒙顿格雷修女医院收治的无AV传导阻滞的病态窦房结综合征患者植入了AAIR起搏器。随访期间测量的结果包括心室导线再次手术的需求、AV传导阻滞的发生率以及因AV传导阻滞导致的心源性猝死发生率。

结果

在此期间,330例患者表现为病态窦房结综合征。87例(26.4%)患者符合标准并接受了AAIR起搏器植入。在平均10.6±0.6年的随访中,78例(91.8%)患者不需要升级。在该组中,31例(39.7%)患者存活,而47例(60.3%)患者在随访结束时因其他合并症死亡。没有猝死归因于AV传导阻滞。只有7例(8.2%)患者需要进行心室导线再次手术:2例(2.4%)因有症状的AV传导阻滞紧急就诊;3例(3.5%)患有房颤需要使用β受体阻滞剂;1例(1.2%)心房导线脱位;1例(1.2%)在电池寿命结束时选择性升级。

结论

本研究观察了AAIR起搏器的安全性,只有2.4%的患者发生AV传导阻滞需要紧急升级。约91.8%的患者仍使用其最初的AAIR起搏器(DANPACE研究的平均随访时间为5.4年,本研究为10.6年)。我们的研究结果与DANPACE研究相似,但我们的结论不同,因为我们认为对于选定的无AV传导阻滞的病态窦房结综合征患者应考虑AAIR起搏。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0770/6211929/2a370adaaf44/medi-97-e12833-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验